Yuhan said on the 20th it signed a $139.82 million (Hanwha 210.2 billion won) contract to supply active pharmaceutical ingredients (API) to Gilead Sciences in the United States.
The drug to be supplied and the disease to be treated were not disclosed. The contract period runs from the 19th of this month to Dec. 31, 2027. There is no upfront payment or advance payment.
Yuhan is expanding API supply, focusing on global pharmaceutical companies. When Yuhan secures an order, its subsidiary Yuhan Chemical Inc. handles actual production.
Yuhan has so far signed a total of four API supply contracts with Gilead. Starting with the supply of API for the human immunodeficiency virus (HIV) preventive injection "Yes2Go" worth 107.7 billion won in Sep. 2024, last year it added two HIV treatments and one hepatitis C treatment contract. The cumulative contract value to date is about $270 million (about 360 billion won).
Recently, Yuhan Chemical Inc.'s production scale has also been growing rapidly. In monetary terms, production expanded from 164.7 billion won in 2023 to 323.9 billion won last year, roughly doubling.
This is due to increased commercial volumes related to Yes2Go. The industry sees the shift from clinical supply to the commercial stage as driving simultaneous increases in production volume and unit price.
On May [day not specified], it also signed a contract worth about 56 billion won with Bridge Biotherapeutics to supply active pharmaceutical ingredients for a cardiomyopathy treatment.